Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 LAMP mRNA dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
The WT1 LAMP mRNA dendritic cell vaccine is an autologous cellular immunotherapy developed by Antwerp University Hospital (UZA) for the treatment of Wilms' Tumor 1 (WT1)-expressing malignancies, including malignant pleural mesothelioma and acute myeloid leukemia (AML). The vaccine is produced by electroporating a patient's own dendritic cells (DCs) with messenger RNA (mRNA) encoding the WT1 antigen. To enhance the potency of the immune response, the WT1 sequence is fused to a Lysosomal-Associated Membrane Protein (LAMP) signal sequence. This modification directs the translated WT1 protein to the lysosomal compartment within the dendritic cell, facilitating efficient processing and presentation of WT1 peptides on MHC class II molecules. This mechanism ensures the activation of both CD4+ helper T cells and CD8+ cytotoxic T cells, aiming to induce a robust and durable anti-tumor immune response against cancer cells overexpressing the WT1 protein.
- Other names
- WT1 mRNA-electroporated dendritic cell vaccineWT-1 mRNA-electroporated dendritic cell vaccineWT 1 mRNA-electroporated dendritic cell vaccineWT1-LAMP mRNA-electroporated autologous dendritic cellsWT-1-LAMP mRNA-electroporated autologous dendritic cellsWT 1-LAMP mRNA-electroporated autologous dendritic cells
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT1 LAMP mRNA dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 LAMP mRNA dendritic cell vaccine.